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In vivo immunization in the mouse with allogeneic  or syngeneic  malignant cells 
results in the development of thymus-derived (T) 1 cytotoxic effector cells (1). Virus- 
induced  murine tumors stimulate both thymus-dependent and thymus-independent 
effector cells during different  phases of tumor development (2, 3). However, injection 
of xenogeneic  cells into the rat has been shown  to raise a population of thymus-in- 
dependent effector cells (4). 
In vitro lymphocytes from nonimmunized donors have been shown to be rendered 
cytotoxic in the presence of target cell-specific antibody (4, 5). The cells participating 
in this type of reaction appear to be members of the thymus-independent population. 
Similarly non-T lymphoid cells from animals immunized with soluble  antigens  are 
cytotoxic in vitro towards target cells coated with the specific antigen (6). 
Patients with transitional cell carcinoma (TCC) of the urinary bladder have been 
shown to possess cytotoxic effector cells in the blood, with specific reactivity for tumor 
cells of relevant origin  (7-11).  Removal of cells carrying Fc receptors and/or surface 
immunoglobulin (Ig), from such cytotoxic lymphocyte preparations results in a loss 
of existing  activity (12). 
The data to be presented here show that after removal of the cells framing 
spontaneous rosettes with sheep erythrocytes (E)  from cytotoxic populations, 
the  tumor-specific activity  lies  in  the  nonrosette-forming  cell  fraction.  This 
procedure is known  to  deplete blood lymphocytes of T  cells  (13,  14)  and  to 
concentrate  the  cell  fraction  which  is  involved  in  antibody-mediated  cyto- 
toxicity (15). 
* Supported by Grant 73:213 from the Swedish Cancer Society. 
1 Abbreviations used in this paper:  E, sheep erythrocytes; EA, erythrocytes coated with 
IgM antibody  without  complement; EAC, erythrocytes  coated with  IgM antibody  plus 
complement; FCS, fetal calf serum; FI, Ficoll-Isopaque solution; MEL-1, primary culture 
of metastatic  melanoma;  MGG,  May-Griinwald Giemsa stain;  PBS, phosphate-buffered 
saline; PHA, phytohemagglutinin; T,  thymus  derived; TCC,  transitional  cell carcinoma; 
and TH, tris-buffered Hanks' solution. 
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Materials and Methods 
In eight separate experiments lymphoid cells from eight patients with clinically verified 
TCC  were compared with those of eight healthy controls. TCC  was staged and graded as 
described previously (9). The clinical situation of the patients is summarized in Table III. 
Preparation  of Effector Cells.--Preparation  of effector cells was  as  described  previously 
(9, 16). About 30 ml of defibrinated blood were obtained from each donor. The bulk of erythro- 
cytes were sedimented on gelatin (17). The leukocyte-plasma supernatant was then incubated 
on a nylon wool column (18) to remove adherent cells. The cells eluted from the column were 
then washed ,three times with Tris-buffered  Hanks's  solution  (TH)  containing 2.5%  fetal 
calf serum (FCS)  (heat-inactivated 60 rain) and counted in Turk's stain. 
Preparation and Fractionation of E Rosette-Forming Cells.--A population of human lympho- 
cytes forming direct rosettes with sheep erythrocytes have the characteristics of T  cells (13, 
19, 20).  E rosettes were formed according to Yata's method (21). A 1% suspension of E washed 
three times in neat FCS was added in equal volumes to a portion of the nylon-purified lympho- 
cytes at a concentration of 5 X  108/ml. The mixture was incubated at 37°C, 15 rain and then 
centrifuged at 400 g for 5 min. Thereafter the packed cells were kept on ice for 60 rain. About 
half the supernatant was removed, then the cells were carefully resnspended and layered onto 
Ficoll-Isopaque solution (FI)  (22)  using an equivalent of 5-7.5  X  108 lymphoid cells/2 ml 
FI in a  15 ml conical centrifuge tube. The tubes were spun at 4012 g for 30 rain, the pelleted 
cells, E rosette forming, and the nonrosette forming, interphase cells, were collected separately 
and washed three times with TH plus 2.5% FCS. Each fraction, together with the same donor 
cells which had not been rosetted, but similarly prepared on FI, were then treated with Tris- 
ammonium chloride solution (23)  to ]yse sheep erythrocytes and remaining human erythro- 
cytes. Each preparation was washed a further three times with TH plus 2.5% FCS. A portion 
of cells from each fraction and from the unfractionated cells from each donor was then re- 
combined with sheep erythrocytes and the rosetting method repeated to check the numbers of 
E  rosetting cells (T) in each preparation. The number of rosette-forming cells was estimated 
on wet and fixed preparations stained with May-Griinwald Giemsa (MGG) in parallel. At 
least 200 lymphoid cells were counted in each preparation, those with 4 or more attached sheep 
erythrocytes were counted as positive.  All rosette-forming cells had the morphological ap- 
pearance of small lymphocytes. 
Complement Receptor.--The  majority of nonthymus processed peripheral lymphoid cells 
possess a  receptor for activated complement C3  (14,  20, 24, 25).  Unfracfionated cells were 
assayed for this receptor as described for human cells by Mellstedt et ai. (26). Equal volumes 
(5 ml) of a 5% suspension of E washed three times and 19S anti-Forssman antibody (Statens 
Bakteriologiska Labotorium,  Stockholm) in subagglutinafing concentration were mixed and 
incubated at 37°C for 60 rain with periodic shaking. The cells were centrifuged, washed two 
times with TH, and then diluted to 5 ml in TH.  2.5 ml were used for EA rosette formation 
(E coated with IgM antibody without complement). To the remaining sheep erythrocytes an 
equal volume of human AB serum diluted 1 : 20 in TH was added. Mter mixing, the cells were 
incubated a further 60 rain at 37°C with occasional shaking. The cells were then washed two 
times in TH. This preparation (erythrocytes coated with IgM antibody plus complement) is 
termed EAC. EA and EAC were then diluted 10 times in TH. Lymphoid cells washed free of 
serum in TH, were used at a  concentration of 1 X  108/0.25 ml and added in equal volumes 
to  EA  and  EAC.  The  mixtures were  centrifuged  at  100  g  for 6 rain and  then incubated 
at 37°C for 15 min. Half the supernatant was removed,  the ceils resuspended, and counted. 
Estimates were performed on 200 cells from each preparation and lymphoid cells with 4  or 
more attached E  were considered rosette forming. Counts were performed on wet and fixed 
preparations stained with MGG. 
Staining  of Effector Cells.--Preparations  from  unfractionated and  fractionated lympho- 
cytes were  checked for contaminating phagocytic cells after staining with acridine orange 
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Cell-Mediated Immunity.--Cell-mediated immunity was assayed in the microplate test as 
described previously (9, 16, 28). 
Tissue Culture Medium.--Target  cells were  cultured  in  monolayers  using  Parker  199 
medium containing 10%  FCS, antibiotics  (100 ILl penicillin and  100/~g  streptomycin/ml), 
and  glutamine 0.3 mg/ml.  For lymphoid  cells medium  199  was  diluted  1:1  with  RPMI 
medium 1640 containing 20 mM Hepes buffer, and supplemented with FCS, antibiotics, and 
glutamine. 
Target Cdls.--Two cell lines formed the basic test material, T24 (9, 29), derived from TCC 
and HCV/29 derived from a  nonmalignant specimen of bladder epithelium,  (established by 
Dr.  J.  FCgh,  Sloan Kettering Institute,  New York).  A primary culture of TCC, J82, was 
tested in passages 4-8. As a  nonbladder target cell control a primary culture of metastatic 
melanoma MEL-I was used in passages  13-16.  All cultures were maintained free of myco- 
plasma. 
Single cell suspensions  were  prepared  by  trypsinization  with 0.02%  EDTA  +  0.05% 
trypsin and washed three times in medium. The cells were added to microplates (Falcon 3034) 
to give 3(}--40 cells/well. These were then incubated 3-4 h at 37°C in humidified air +  5% CO2 
during which time cell attachment was completed, plating efficiency  of the target cells was 
> 90%. The plates were then inverted for 20 rain and the medium dumped off. Effector cell 
preparations in concentrations of 1 and 0.5  X  106 eells/ml were then added in 10 #1 volumes 
to the target cells. 12 wells  were used for each effector  cellpreparation at a given  concentration. 
The plates were incubated for 24 h at 37°C in humidified air +  5% CO2 • At termination 
of the experiment they were inverted for 30 rain, the medium dumped off, and then washed 
gently with PBS, pH 7.2. The residual target cells were fixed and stained with MGG. 
Estimation of Cytotoxicity.--In each experiment the arithmetic mean of the surviving target 
cells in wells which had contained patients' lymphoid cells was compared with that in wells 
having contained control donors'  cells at  equivalent concentrations,  for each  effector  cell 
preparation. The significance  of differences  was estimated by Student's t test with P  _  0.05 
considered as significant. Cytotoxicity is expressed as the percent of reduction =  (1 -- P/C) X 
100  (P  =  mean surviving target cells after incubation with patients' lymphoid cells; C  = 
mean surviving target cells after incubation with control donors' lymphoid cells). 
Antibody-Dependent Cytotoxicity.--Unfractionated and fractionated lymphoid cell prepara- 
tions from two patients and one control were tested for ability to mediate antibody dependent 
lysis of target cells (30). 1 )< 106 Chang liver cells in 1-ml tissue culture medium were labeled 
with 100/zCi sodium chromate (specific radioactivity 100-300 mCi/mg Cr) for 40 rain at 37°C. 
The cells were then washed three times in medium.  Cytotoxicity was tested in 15-ml conical 
plastic centrifuge tubes each containing 25  X  103 labeled target cells.  Lymphoid cells were 
tested at a ratio of 30:1 to the target cells. Heat-inactivated (56°C, 60 rain)  rabbit anti-Chang 
serum was used at a final diluation of 3  X  10- 4.  The total incubation volume was 1.5 ml. 
Each parameter was tested in duplicate tubes. The tubes were incubated 18-20 h in humidified 
air +  5% CO2 • Cytotoxicity is expressed as the corrected isotope release after subtraction of 
the background release in target cell controls incubated with medium only  (range 18-23%). 
Maximum variation between duplicate tubes was -4-3%. 
PHA-Induced Cytotoxidty.--Unfractionated and  fractionated  lymphocyte  preparations 
were tested for cytotoxic activity towards Chang cells in the presence of phytohemagglutinin 
(PHA)  (30). These tests were carried out in parallel with those for antibody-mediated cyto- 
toxicity. PHA (purified  PHA-W, Wellcome Research Labs., England) was added to the incu- 
bation mixtures in doses of 0.1/~g and 1 #g. 
RESULTS 
Characterization  of Unfr  actionated  and Fr  actionated  Populations According to 
Surface  Markers.--Purified  lymphocyte  preparations  were  characterized  ac- 
cording to two surface markers, capacity to form E  and EAC rosettes. As shown 460  TUMOR-SPECIfIC  CYTOTOXICITY 
in Table I  these preparations from both patients and control donors had the 
proportions of cells carrying these markers described previously for normal 
human peripheral blood l)znphocyte preparations (13,  14, 20,  24). After sedi- 
mentation of E  rosette-forming cells in FI and removal of E  by NH4CI lysis, 
the pelleted cells were found to contain 90 % or more cells capable of reforming 
E rosettes. In this fraction <4 % of the cells formed EAC rosettes. Conversely, 
the interphase fraction was seen to contain <: 7 % E  rosette-forming cells,  but 
76 % of these cells could form EAC rosettes. These observations are summarized 
in  Table I.  In  all  eight  experiments the average numbers of E  rosette- and 
EAC rosette-forming cells in both unfractionated preparations and in the two 
fractions from patients and controls were similar. The mean values with the 
standard deviation were as follows: for E rosettes unfractionated cells 76 4-  6, 
TABLE  I 
Surface Markers of Lympkocyte Fractions 
Donor  Fraction 
Rosette-formlng cells 
EAC  E 
Normal 
Ca. bladder 
%  % 
Unfracfionated  18  74 
Pellet  4  90 
Interphase  76  7 
Unfractionated  20  72 
Pellet  4  90 
Interphase  76  6 
pellet 92 4- 7, and interphase 9 4- 5; and for EAC rosettes unfractionated cells 
25 4- 3, pellet 3 4-  1, and interphase 76 4- 2.5.  Representative values for one 
patient and control are shown in Table I. 50-70 % of the starting populations 
of E rosette- and non-E rosette-forming cells were recovered after fractionation. 
Morphologically the cells obtained after nylon wool purification and fractiona- 
tion were > 95 % lyrnphocytes. 
Cytatoxic Potential of the  Cell  Fractions.--It  has previously been  reported 
(16)  that lymphocytes from both normal donors and patients prepared by FI 
cause a high nonspecific cytotoxicity in the microplate assay as compared with 
the same donors' ceils prepared by nylon wool purification. This cytotoxicity 
does not relate to differences in purity of the effector cell preparations,  and 
becomes manifest at high effector cell: target cell ratios and after incubation 
periods of 2 days or more. To avoid these nonspecific effects in this series of 
experiments the effector target cell ratios were kept relatively low (125:1 and 
250:1) and the incubation time of the assay was also shortened to 24 h. Under 
these conditions the mean surviving number of target cells incubated in medium 
only compared well with that in wells having contained control effector cells 
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125:1  63 
250:1  24 
125:1  33 
250:1  50 
125:1  52 
250:1  54 
125:1  61 
250:1  50 
125:1  50 
250:1128 
125:1}36 
250:1  44 
125:1  40 
250:1  36 
125:1  36 
Surviving target cells 
per well* 
Patient  Control 
(mean  :t:: SE) 
464-2.9  654-2 
60  4-  2.3  70  4-  2.7 
634-3  67  4-3.5 
76  4-  3.3  73  -I- 2.5 
21  4-  1.1  66  4-  2.5 
34  4-  4  70  4-  3.5 
57  4-  2  75  4-  3.2 
56  4-  2.2  71  4-  3.7 
64  4-  1.9  63  4-  2.3 
4-  1.9  62  4-  1.3 
4-  1.9  57  4-  2.7 
4-  3.5  70  ±  2.5 
4-  4.5  54  4-  3.8 
4-  3.3  53  4-  2.6 
4-3  56  4-3.8 
4-  2.3  58  4-  2.8 
4-  3.7  52  4-  3.4 
4-  4.6  54  4-3 
4-  2.4  28  4-2 
4-6  32  4-  2.4 
4-  4  42  4-3.6 
4-  3.2  40  4-  2.4 
4-  3.2  24  4-  2.4 


































* Surviving  target cells incubated  with medium  only  (mean 
61.5 -4- 3; HCV/29, 56 4- 5; and MEL-1, 44 4- 3. 
:~ Estimated as described in Materials  and Methods. 
§ N.S. not significant. 
+SE)  J82,  62  4-  4; T24, 
Before fractionation lymphocytes from six of the  eight patients  with TCC 
showed tumor-specific cytotoxicity (Table III). After fractionation,  all meas- 
urable cytotoxicity was recovered in the interphase  (non-E rosetting) prepara- 
tion in all cases. In four patients this fraction gave increased levels of specific 
cytotoxicity as compared with the unfractionated  cells at equivalent effector: 
target  cell ratios.  This is  exemplified in  Table  II and  was  observed in  three 
additional experiments. In two experiments the cytotoxicity produced  by the 
interphase  fraction remained at  the same level as in the unfractionated  cells. 
No  tumor-specific  cytotoxicity  was  detectable  in  the  pelleted  fraction  (E 462  TUMOR-SPECIFIC  CYTOTOXICITY 
rosette-forming cells)  of any patient.  Lymphocytes from  the  control  donors 
showed no specific activity either before or after fractionation. 
Functional Activity of Cell Fractions in Anlibody-Mediated and PHA-Induced 
Cytotoxicity.--As  shown  in  Table  IV  cytotoxicity  mediated  by  rabbit  IgG 
antibody to Chang cells was obtained in this assay with the unfractionated and 
interphase cells only.  The pelleted  (E rosette-forming population)  showed no 
significant reactivity. In fact a clear enhancement of cytotoxicity was produced 
by the  interphase  cells.  The  results  are in  agreement with  those previously 
published  (15)  and  show  that  the  lymphoid cell  type predominating  in  this 
reaction has non-T characteristics (4, 5). 
TABLE  III 
Summary of Patients with TCC Tested in Fractionation Experiments 
Patient  Clinical situation* 
Tumor-specific cytotoxicity of lymphocyte fractions:~ 
Unfractionated  Interphase  Pellet 
1  T3 M3  28  33  0 
2  T2 M2  18  62  0 
3  T1 M1  0  0  0 
4  T3 M3  30  32  0 
5  T2 M1  17  30  0 
6  T4 M3  29  68  0 
7  T4 with metastases  0  0  0 
8  T2 M2  15  37  0 
* For details see Materials and Methods. All patients had tumor present at the time of 
testing. 
:~ Percent reduction at an effector:target cell ratio of 250:1. 
It has previously been demonstrated that the E  rosette-forming cells have an 
increased reactivity to PHA as measured by DNA-synthesis (13). The capacity 
of purified lymphocytes before and after fractionation to participate in PHA- 
induced cytotoxicity is shown in Table V. The pelleted cells (E rosette-forming 
fraction) show a moderately increased reactivity in this test as compared with 
the  unfractionated  cells.  The  interphase  cells give a  reduced  but  significant 
cytotoxic effect also. 
DISCUSSION 
These  results  confirm  and  complement previous  observations  (12)  which 
showed that the effector cells in this tumor-specific reaction reside in the non- 
thymus-derived population of peripheral lymphocytes. Thus cytotoxicity was 
lost  after  removal  of lymphocytes with  Fc  receptors  and/or  surface  Ig  on 
columns coated with human Ig and rabbit anti-human Ig in excess. 
In the present series of experiments it is seen that removal of lymphocytes 
capable of forming direct E  rosettes does not reduce existing cytotoxicity, in C.  O'TOOLE, V.  STEJSKAL,  P.  PERLMANN,  M.  KARLSSON  463 
TABLE IV 
Activity of Lymphocyte Fractiom in Antibody-Mediated C~totoxicity 
Fraction 
Cytotoxicity* 
Chang cells  Chang cells +  AS~ 
Unfractionated  7  26 
Pellet  1  3 
Interphase  10  40 
* Isotope release corrected by subtracting release in lymphocyte-free  controls. Incubation 
for 18 h. 
~; AS, antiserum present. See Materials and Methods. 
TABLE V 
Activity of Lymphocyte Fractions in PtIA-Induced Cytotoxicity 
Fraction 
5tCr release from Chang cells* 
Medium  0.1 pg FHA  1 #g FHA 
Unfractionated  1  20  29 
Pellet  -  2  26  38 
Interphase  -  1  14  8 
* Corrected by subtracting release in lymphocyte-free  controls. Incubation for 18 h. 
fact increased reactivity is often found in  the residual  cells.  The E  rosette- 
forming cells in human blood have the characteristics of thymus-derived cells 
(13,  14, 20). 
The lymphocyte populations were identified before and after fractionation 
according to a second surface marker, the capacity to bind EAC  (14,  20,  24, 
25).  The  distribution  of  this  marker  predominantly  in  the  non-E  rosette- 
forming interphase fraction provides additional  evidence for the nonthymus 
origin of the effector cells in this tumor-specific reaction. 
Morphologically non-T cells in human blood have been identified on the basis 
of surface Ig, the possession of receptors for activated complement, and for Ig 
aggregates (31). On a functional level cells carrying the C3 receptor are known 
to participate in  antibody-mediated cell lysis  (15,  32).  In  the latter  type of 
reaction an intact Fc portion is required on the inducing antibody (33, 34) indi- 
cating that the effector cells carry a receptor for Fc. The loss of tumor-specific 
cytotoxicity after removal of lymphocytes with Fc receptors and/or surface Ig 
(12)  indicate that the same cell type may be operative in this situation. Anti- 
body-mediated cytotoxicity by nonimmune lymphocytes has been  shown  to 
require Fc receptor-bearing cell but not Ig-bearing cells per se (15, 35). A  strict 
classification of  the  thymus-independent effector cells in  this  tumor-specific 
cytotoxicity must therefore await further functional analysis. 
The increased levels of tumor-specific cytotoxicity often observed after the 
depletion of T cells speaks against, but does not formally rule out, T-cell partic- 464  TUMOR-SPECIFIC CYTOTOXICITY 
ipation at the  effector cell level. The pelleted E  rosette-forming cells, although 
totally ineffective in tumor-specific cytotoxicity, retain their capacity to react 
in PHA-induced  cytotoxicity. This  suggests  that  there  is  no  functional  im- 
pairment of these cells due to preparative treatment. That the interphase cells 
(non-T) also respond, but to a lesser extent, in PHA-induced cytotoxicity, may 
be explained  either by the capacity of B  cells to respond to PHA  (36)  or on 
the basis of residual T  cells in this fraction. That PHA can induce cytotoxicity 
in lymphocytes free of T  cells has been described (37). 
A  sequential  development of thymus-derived and  thymus-independent ef- 
lector cells has been described during the development of a viral induced murine 
tumor (2). The assay used was similar to that in the present experiments. In a 
~Cr release assay in a  similar system (3)  a predominantly T-cell cytotoxicity 
has been reported. The type of effector cell detected may therefore be influenced 
by  the  assay  employed. However,  the  duration  and  intensity of  antigenic 
stimulation in vivo during different phases of tumorigenesis may determine the 
type of effector cells which  predominate. In  the  human  patient  with  estab- 
lished TCC a prolonged contact with tumor antigen(s) can be inferred. 
SUMMARY 
Peripheral lymphocytes from patients with urinary bladder carcinoma and 
controls have  been  separated  on  the  basis  of rosette  formation with  sheep 
erythrocytes. The fractions were tested for tumor-specific cytotoxicity. The E 
rosette-forming cells of purity  _>  90%  respond  well  in  PHA-induced  cyto- 
toxicity but are totally inactive in the tumor assay. The non-E rosette-forming 
cells (purity _>  91%) give enhanced activity in the tumor-specific cytotoxicity 
as well as in antibody-mediated target cell lysis in a model system. These data 
support  the notion  that  the effector cells in  cell-mediated immunity to car- 
cinoma of the urinary bladder are members of the nonthymus-derived popula- 
tion of peripheral lymphocytes. 
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